Sinemet CR Related Published Studies
Well-designed clinical trials related to Sinemet CR (Carbidopa / Levodopa)
Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome. [2007.11]
Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: Two double-blind, randomized, clinical trials. [2007.05.11]
Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. [2005.05]
Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa. [2004.01]
[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study] [2003.06]
The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. [2000.05]
Occlusion and levodopa-carbidopa treatment for childhood amblyopia. [1998.10]
Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. [1997]
Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. [1996.07]
International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease. [1996.03]
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. [1995.02]
Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. [1994.07]
A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. [1994.01]
Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa. [1992]
Clinical efficacy of Sinemet CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open, and a double-blind, double-dummy, multicenter treatment evaluation. The Dutch Sinemet CR Study Group. [1992]
Characterisation of the in vivo behaviour of a controlled-release formulation of levodopa (Sinemet CR). [1991.08]
Standard and controlled-release levodopa/carbidopa in patients with fluctuating Parkinson's disease on a protein redistribution diet. A preliminary report. [1991.04]
Sinemet CR in Parkinson's disease. [1991.01]
Randomized double-blind cross-over study of Sinemet-controlled release (CR4 50/200) versus Sinemet 25/100 in Parkinson's disease. [1990]
Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease. [1989.11]
Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. [1989]
Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease. [1988.09]
Well-designed clinical trials possibly related to Sinemet CR (Carbidopa / Levodopa)
Levodopa pharmacotherapy for cocaine dependence: Choosing the optimal behavioral therapy platform. [2008.04.01]
Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. [2008.01]
Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease. [2007.09]
Mood-elevating effects of d-amphetamine and incentive salience: the effect of acute dopamine precursor depletion. [2007.03]
Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease. [2004.10]
Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. [2004.01]
Randomized trial of pallidotomy versus medical therapy for Parkinson's disease. [2003.05]
Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease. [2002.03]
Endurance performance in humans: the effect of a dopamine precursor or a specific serotonin (5-HT2A/2C) antagonist. [1997.11]
Objective measurement of activation of rigidity: diagnostic, pathogenetic and therapeutic implications in parkinsonism. [1996.06]
Controversies in the therapy of Parkinson's disease. [1996]
The effect of deprenyl and levodopa on the progression of Parkinson's disease. [1995.11]
Comparison between a fast and a slow release preparation of levodopa and a combination of the two: a clinical and pharmacokinetic study. [1994.02]
Defining small differences in efficacy between anti-parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor. [1993.04]
Hereditary motor and sensory neuropathy with treatable extrapyramidal features. [1992.02]
Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. Preliminary findings in 20 patients. [1992]
Comparative multiple-dose pharmacokinetics of controlled-release levodopa products. [1992]
The effect of dietary protein on the efficacy of L-dopa: a double-blind study. [1989.04]
Other research related to Sinemet CR (Carbidopa / Levodopa)
Acute overdose with controlled-release levodopa-carbidopa. [2008.03]
Carbidopa/levodopa-responsive myoclonus. [2007.02.15]
The effect of levodopa or levodopa-carbidopa (sinemet) on fracture healing. [2006.07]
Other possibly related research studies
[Prevention and treatment of fluctuations in patients with Parkinson's disease] [2006.12.20]
Levodopa can worsen tremor associated with dystonia. [2006.10]
Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. [2006.03]
[18F]FDOPA PET and clinical features in parkinsonism due to manganism. [2005.04]
Dopa-responsive dystonia presenting as delayed and awkward gait. [2008.04]
Interaction between levodopa and enteral nutrition. [2008.03]
Two cases of rapid onset Parkinson's syndrome following toxic ingestion of ethylene glycol and methanol. [2007.01]
Restless legs syndrome. [2008.07.15]
|
